EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Microbiome–Immune Interactions as Determinants of Checkpoint Inhibitor Efficacy in Hepatocellular Carcinoma

Madalina Raluca Ostafe iD, Simona Ruxandra Volovat, Ana Clement, Cezara Ioana Litcanu, Smaranda Iuliana Tabarcea, Cristian Constantin Volovat, Diana-Ioana Panaite iD, Iolanda Georgiana Augustin, Constantin Volovat

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27177543 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Madalina Raluca Ostafe und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology-Radiotherapy, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Immune Checkpoint Inhibitors, Gastrointestinal Microbiome. Die Arbeit nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) remains a major global health challenge and one of the leading causes of cancer-related mortality, with advanced disease continuing to be associated with limited therapeutic options and substantial heterogeneity in response to systemic treatment. Recent evidence has established the gut microbiota, through the gut–liver axis, as a critical determinant of immunotherapy efficacy, while also influencing antitumor immunity and liver carcinogenesis. Microbial dysbiosis may promote chronic inflammation, intestinal barrier disruption, bacterial translocation, and immune dysfunction, thereby contributing to hepatocarcinogenesis. Moreover, gut microbial composition and microbial-derived metabolites, including bile acids, short-chain fatty acids (SCFAs), and inosine, have been associated with modulation of antitumor immune responses and differential outcomes to immune checkpoint inhibitors (ICIs). Emerging clinical evidence in HCC has identified distinct gut microbial signatures associated with response to nivolumab, pembrolizumab, and atezolizumab-based regimens, including enrichment of Akkermansia muciniphila and SCFA-producing taxa such as Ruminococcaceae, Roseburia, and Prevotella in responders. However, these findings remain inconsistent across studies, with no reproducible microbial signature identified because of small cohort sizes, heterogeneous patient populations, geographic variation, cirrhosis-related confounding factors, and methodological differences in microbiome analysis. This review summarizes the current understanding of microbiome–immune interactions in HCC, examines mechanistic pathways linking the microbiota to immunotherapy response, critically evaluates available clinical evidence, and discusses current limitations and future therapeutic strategies, including fecal microbiota transplantation, probiotics, dietary modulation, and engineered bacterial platforms. Collectively, microbiome-based approaches may contribute to the development of personalized immunotherapeutic strategies in HCC, although larger standardized prospective studies are required before microbiome-derived biomarkers can be implemented in routine clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsCarcinoma, HepatocellularImmune Checkpoint InhibitorsGastrointestinal MicrobiomeHumansDysbiosisAnimalsImmunotherapy

Stichwörter der Autor:innen

bile acidsdysbiosisfecal microbiota transplantationgut microbiotagut–liver axishepatocellular carcinomaimmune checkpoint inhibitorsimmunotherapymicrobiomeprecision oncology

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Medical Oncology-Radiotherapy, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
  • Regional Institute of Oncology, 700483 Iasi, Romania.
  • Department of Radiology, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
  • Department of Oncology, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.

ORCID-Profile: Madalina Raluca Ostafe, Diana-Ioana Panaite

Zitieren

APA

Ostafe, M. R., Volovat, S. R., Clement, A., Litcanu, C. I., Tabarcea, S. I., Volovat, C. C., Panaite, D. I., Augustin, I. G., & Volovat, C. (2026). Microbiome–Immune Interactions as Determinants of Checkpoint Inhibitor Efficacy in Hepatocellular Carcinoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27177543

Vancouver

Ostafe MR, Volovat SR, Clement A, Litcanu CI, Tabarcea SI, Volovat CC, et al. Microbiome–Immune Interactions as Determinants of Checkpoint Inhibitor Efficacy in Hepatocellular Carcinoma. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27177543

BibTeX
@article{Ostafe2026,
  author = {Ostafe, Madalina Raluca and Volovat, Simona Ruxandra and Clement, Ana and Litcanu, Cezara Ioana and Tabarcea, Smaranda Iuliana and Volovat, Cristian Constantin and Panaite, Diana-Ioana and Augustin, Iolanda Georgiana and Volovat, Constantin},
  title = {Microbiome–Immune Interactions as Determinants of Checkpoint Inhibitor Efficacy in Hepatocellular Carcinoma},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27177543}
}
Kostenlos starten →